AR and breast cancer: We have shown via silencing and overexpression approaches that FOXA1 is critical for AR to have oncogenic activity in MDA-MB-453 cells [20, 71, 72], but whether knockdown of FOXA1 would facilitate AR/GATA3 interactions and AR-mediated tumor suppressor activity in this or any other breast cancer context is unknown.